drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (gene-modified biologic)
drug_description
Gene-modified natural killer cells expressing a chimeric antigen receptor targeting CD19 to redirect NK cytotoxicity against CD19+ B cells; administered as cellular immunotherapy to deplete autoreactive B cells.
nci_thesaurus_concept_id
C170903
nci_thesaurus_definition
A preparation of natural killer (NK) cells engineered to express an inhibitory chimeric antigen receptor (iCAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 iCAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The iCAR is designed to spare normal cells from NK cell actions by including an inhibitory receptor that is activated upon binding to antigens that are present on normal cells only. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Receptors, Chimeric Antigen
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Gene-modified natural killer cells expressing an anti‑CD19 chimeric antigen receptor redirect NK cytotoxicity to CD19+ B cells in an MHC‑independent manner, inducing perforin/granzyme‑mediated killing of naive, memory, and plasmablast B‑cell subsets to deplete autoreactive B cells and reduce autoantibody production and B‑cell antigen presentation.
drug_name
Anti-CD19 CAR NK cells
nct_id_drug_ref
NCT06464679